{"preliminary_commentary":{"by_channel":{"bluesky_thread":67,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05358639\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT05358639","nct_id":"NCT05358639","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05358639. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily (bid). Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated. Navitoclax will be administered daily. The initial dose of olaparib 200 mg has been selected after considering the single agent Phase I/II dose based and on ongoing combination studies on expected toxicity and evidence for reduced PARP inhibition","label":"Single","type":"EXPERIMENTAL"}],"collaborators":["Exactis Innovation","Centre hospitalier de l'Université de Montréal (CHUM)","Princess Margaret Hospital, Canada"],"completion_date":{"date":"2025-04-28","type":"ESTIMATED"},"conditions":["High Grade Serous Carcinoma","Triple Negative Breast Cancer","Ovarian Cancer"],"enrollment":{"count":36,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Olaparib tablet","otherNames":["Lynparza"],"type":"DRUG"},{"name":"Navitoclax","otherNames":["ABT-263"],"type":"DRUG"}],"last_update":"2024-11-18","lead_sponsor":"Sunnybrook Health Sciences Centre","official_title":"A Phase I Trial of the Combination of Olaparib and Navitoclax in Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-03-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To define a dose and schedule of navitoclax (Recommended Phase II Dose, RP2D) that can be combined safely with Olaparib in women with metastatic recurrent high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) for further study","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2022-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination of Olaparib and Navitoclax in Women with HGSC and TNBC","url":"https://clinicaltrials.gov/study/NCT05358639"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05358639"}